online Βιβλιοπωλείο
Δεν υπάρχουν προϊόντα στο καλάθι σας.
Close
Filters
Σύνθετη Αναζήτηση

The ESC Textbook of Cardiovascular Medicine

ISBN: 9780198784906
This new, third edition of The ESC Textbook of Cardiovascular Medicine is a ground-breaking initiative from the European Society of Cardiology that transforms reference publishing in cardiovascular medicine to better serve the changing needs of the global cardiology community. Providing the background information behind clinical practice and the ESC Clinical Practice Guidelines, this publication is an invaluable resource for cardiologists across the world.
€279,50
+ -
  • Provides the background information behind clinical practice through in-depth, peer-reviewed chapters, and broad coverage of the field
  • Includes contributions from more than 1000 of the world's leading specialists in cardiology
  • Accompanied by free access to the digital publication, ESC CardioMed, which will be continually updated by the author team
  • Highly illustrated with multi-media features, including over 350 videos, embedded in the text
  • Cross-referenced links to ESC Clinical Practice Guidelines, related content, and primary research data in European Heart Journal via ESC CardioMed

New to this Edition:

  • Completely revamped table of contents covering over 63 disciplines within cardiology
  • Now split into six key parts: Introduction to the cardiovascular system; Investigations; Heart diseases; Vascular disease; Specific populations - gender and race; and Other aspects of cardiology
  • Provides the background information behind clinical practice through in-depth, peer-reviewed chapters, and broad coverage of the field
  • Includes contributions from more than 1000 of the world's leading specialists in cardiology
  • Accompanied by free access to the digital publication, ESC CardioMed, which will be continually updated by the author team
  • Highly illustrated with multi-media features, including over 350 videos, embedded in the text
  • Cross-referenced links to ESC Clinical Practice Guidelines, related content, and primary research data in European Heart Journal via ESC CardioMed

New to this Edition:

  • Completely revamped table of contents covering over 63 disciplines within cardiology
  • Now split into six key parts: Introduction to the cardiovascular system; Investigations; Heart diseases; Vascular disease; Specific populations - gender and race; and Other aspects of cardiology
  • PART 1. Introduction to the cardiovascular system
  • Section 1. Cardiovascular history and physical examination
  • Section editor: Nicholas Boon
  • 1.1: Andrew Elder, Nicholas A. Boon, and Alan G. Japp: Approach to cardiovascular assessment
  • 1.2: Alan G. Japp, Iain Simpson, Stephen Pettit, Arthur Yue, and Junaid Zaman: Cardiovascular symptoms
  • 1.3: Stuart Pringle, Samantha Fitzsimmons, Ingibjorg Gudmundsdottir, and Joseph B. Esterson: Cardiovascular signs
  • Section 2. Developmental biology of the heart
  • Section editor: Miguel Torres
  • 2.1: Robert G. Kelly: Cardiac embryogenesis
  • 2.2: Miguel Torres: The molecular basis of cardiac embryogenesis
  • 2.3: Maurice J. B. van den Hoff and Antoon F. M. Moorman: From heart-forming region to ballooning chambers
  • 2.4: José M. Pérez-Pomares and José L. de la Pompa: Development of the ventricles and valves
  • 2.5: Jan Hendrik van Weerd and Vincent M. Christoffels: Development of the cardiac conduction system
  • 2.6: Thomas J. Cahill and Paul R. Riley: Epicardial and coronary vascular development
  • 2.7: Mark H. Soonpaa and Loren J. Field: Cardiomyocyte development from mid-gestation through preadolescence
  • Section 3. Functional anatomy of the heart
  • Section editor: Siew Yen Ho
  • 3.1: Sabine Ernst and Siew Yen Ho: Introduction
  • 3.2: Ammar M. Killu and Samuel J. Asirvatham: Cardiac anatomy in the interventional era: an overview
  • 3.3: Taka-aki Matsuyama and Hatsue Ishibashi-Ueda: Normal conduction system, coronary arteries, and coronary veins
  • 3.4: Damian Sanchez-Quintana and José Angel Cabrera: Normal atrial and ventricular myocardial structures
  • 3.5: Philip J. Kilner and Sonya V. Babu-Narayan: The heart as a functional unit
  • 3.6: Philip J. Kilner and Sonya V. Babu-Narayan: Ventricular structure and function
  • 3.7: Luigi Badano and Denisa Muraru: Functional anatomy of atria
  • 3.8: Fahd Makhdom, Pascal Thériault-Lauzier, Siew Yen Ho, and Nicolo Piazza: Functional anatomy of left heart valves
  • 3.9: Christine Selton-Suty, Olivier Huttin, Clément Venner, and Yves Juillière: Functional anatomy of right heart valves
  • 3.10: Robert Manka and Sabrina Oebel: Functional anatomy of myocardial perfusion
  • Section 4. Cardiovascular physiology
  • Section editor: Guido Grassi
  • 4.1: Sándor J. Kovács: The heart as a pump: governing principles
  • 4.2: Marek Malik: Cardiac electrophysiology
  • 4.3: Christian Seiler: Cardiovascular physiology: regulation of coronary circulation
  • 4.4: Gino Seravalle and Guido Grassi: Regulation of blood pressure
  • 4.5: Markus P. Schlaich: Heart/kidney interactions
  • 4.6: Ross Arena, Dejana Popovic, Marco Guazzi, Amy McNeil, and Michael Sagner: Cardiovascular response to exercise
  • 4.7: Jens Barthelmes and Isabella Sudano: Cardiovascular response to mental stress
  • 4.8: Naima Covassin and Virend K. Somers: The cardiovascular system during sleep
  • 4.9: Magnus Bäck, Laure Joly, Nicolas Sadoul, and Athanase Benetos: The ageing heart
  • 4.10: Sebastian Ewen, Saarraaken Kulenthiran, and Felix Mahfoud: Alterations in cardiovascular physiology in pathological states
  • Section 5. Cardiovascular pharmacology
  • Section editor: Faiez Zannad
  • 5.1: João Pedro Ferreira and Patrick Rossignol: Renin-angiotensin system and neprilysin
  • 5.2: Faiez Zannad and João Pedro Ferreira: Mineralocorticoid receptor antagonists
  • 5.3: Atul Pathak: Autonomic nervous system drugs
  • 5.4: Stéphane Laurent: Pharmacology of vasodilators
  • 5.5: Mattia Arrigo and Alexandre Mebazaa: Positive inotropes
  • 5.6: Federico Guerra and Alessandro Capucci: Antiarrhythmics
  • 5.7: Tabassome Simon: Pharmacology of oral antiplatelet drugs
  • 5.8: Freek W. A. Verheugt: Fibrinolytic therapy
  • 5.9: Cesare R. Sirtori and Massimiliano Ruscica: Lipid-lowering drugs
  • 5.10: Pierre-Jean Saulnier and Samy Hadjadj: Oral diabetes treatments and cardiovascular disease
  • 5.11: Kevin Damman: Renal pharmacology for the cardiologist
  • 5.12: Keld P. Kjeldsen, Juan Tamargo, and Thomas Andersen Schmidt: Potassium binders
  • 5.13: Pauline Bosco-Levy, Julien Bezin, Francesco Salvo, and Nicholas Moore: Cardiovascular effects of non-cardiovascular drugs
  • 5.14: Jeffrey K. Aronson: Drug-drug interactions
  • 5.15: Jonathan Michel and Robert A. Byrne: Local drugs in interventional cardiology pharmacology
  • Section 6. Anticoagulation
  • Section editor: Raffaele DeCaterina
  • 6.1: Pier Mannuccio Mannucci: An overview of haemostasis, in relation to atherothrombotic, thromboembolic, and venous cardiovascular disease
  • 6.2: Fedor Bachmann: Current targets of anticoagulants
  • 6.3: Renate Schnabel, Dipak Kotecha, and Paulus Kirchhof: Epidemiology of non-vitamin K antagonist oral anticoagulants in heart disease
  • 6.4: Freek W. A. Verheugt: Unfractionated heparin
  • 6.5: Paul Guedeney, Mathieu Kerneis, Johanne Silvain, Gilles Montalescot, and Jean-Philippe Collet: Low-molecular-weight heparin
  • 6.6: Michiel Coppens: Fondaparinux and its derivatives
  • 6.7: Davide Capodanno: Bivalirudin and argatroban
  • 6.8: Marcel Levi: Reversal of parenteral anticoagulants
  • 6.9: Jørgen Jespersen and Jane Skov: Vitamin K antagonists
  • 6.10: Thomas Vanassche and Peter Verhamme: The NOACs: pharmacodynamics and pharmacokinetics
  • 6.11: Jeffrey Weitz: The NOACs: clinical pharmacology
  • 6.12: Felicita Andreotti, Eliano Pio Navarese, and Filippo Crea: The NOACs in special situations: the elderly, renal impairment, and combination with antiplatelet agents or thrombolysis
  • 6.13: Joanne van Ryn: Reversal of oral anticoagulants
  • 6.14: Christina Reith and Colin Baigent: Epidemiological data on the use of traditional anticoagulants in cardiovascular disease
  • Section 7. Epidemiology and global burden
  • Section editor: Sumeet Chugh
  • 7.1: Sumeet S. Chugh: Strategies for assessment of global disease burden
  • 7.2: George A. Mensah: Epidemiology and global burden of hypertension
  • 7.3: Andrew E. Moran: Epidemiology and global burden of ischaemic heart disease
  • 7.4: James D. Wilkinson, Ashwin Kumar, Joslyn A. Westphal, Jason D. Czachor, Hiedy Razoky, and Steven E. Lipshultz: Epidemiology and global burden of cardiomyopathy
  • 7.5: Aapo L. Aro and Sumeet S. Chugh: Epidemiology and global burden of arrhythmias
  • 7.6: Dianne Sika-Paotonu, Andrea Beaton , and Jonathan Carapetis: Epidemiology and global burden of rheumatic heart disease
  • 7.7: Siva Ketha and Leslie T. Cooper: Epidemiology and global burden of myocarditis and pericarditis
  • 7.8: Imad M. Tleyjeh and Aref A. Bin Abdulhak: Epidemiology and global burden of infective endocarditis
  • 7.9: Holger Reinecke: Epidemiology and global burden of peripheral arterial disease and aortic aneurysms
  • PART 2. Investigations
  • Section 8. Electrocardiogram
  • Section editor: Antonio Bayes de Luna
  • 8.1: Antonio Bayes de Luna: Introduction
  • 8.2: Adrian Baranchuk and Bryce Alexander: Atrial abnormalities
  • 8.3: Ljuba Bacharova and Harvey Estes: Ventricular hypertrophy
  • 8.4: Antonio Bayes de Luna and Marcelo Elizari: Intraventricular conduction disturbances
  • 8.5: Miguel Fiol and Antonio Bayes de Luna: ECG patterns of ischemia and necrosis
  • 8.6: Wojciech Zareba and Pyotr Platonov: ECG patterns related to arrhythmias and sudden death: channelopathies, early repolarization, and preexcitiation
  • 8.7: Angel Moya: ECG in syncope, palpitations, dyspnea and chest pain
  • 8.8: Antonio Bayes de Luna and Günter Breithardt: The ECG abnormal in patients without heart disease and the ECG normal in presence of evident structural heart disease
  • Section 9. Chest radiography
  • Section editor: Christian Herold
  • 9.1: Christian Loewe and Dietrich Beitzke: Normal anatomy with a focus on the cardiac silhouette and the great vessels
  • 9.2: Massimo Pistolesi and Mariaelena Occhipinti: Pulmonary venous hypertension
  • 9.3: Thomas Henzler: Pulmonary arterial hypertension and acute and chronic thromboembolism
  • 9.4: Tomas Franquet: Pulmonary infections
  • 9.5: Nicola Sverzellati, Gianluca Milanese, and Mario Silva: Focal abnormalities
  • 9.6: Nicholas Screaton and Gianluca Milanese, and Mario Silva: Lines, tubes, and implantable devices
  • Section 10. Cardiac ultrasound
  • Frank Flachskampf
  • 10.1: Jens-Uwe Voigt: Principles of echocardiographic imaging and velocity assessment by Doppler and speckle tracking
  • 10.2: Thomas Binder: Technical equipment for echocardiography
  • 10.3: Thomas Binder: Transthoracic echocardiography and the standard examination of specific cardiac structures
  • 10.4: Roxy Senior and Nikolaos Karogiannis: Stress echocardiography
  • 10.5: Anastasia Vamvakidou and Roxy Senior: Contrast echocardiography
  • 10.6: Francesco F. Faletra, Laura A. Leo, Tiziano Moccetti, and Mark J. Monaghan: Three-dimensional echocardiography
  • 10.7: Thomas H. Marwick: Coronary heart disease
  • 10.8: Laura Ernande: Hypertension and diabetes
  • 10.9: Ruxandra Beyer and Frank A. Flachskampf: Transoesophageal echocardiography
  • 10.10: Jens-Uwe Voigt: Left ventricular function, heart failure, and resynchronization therapy
  • 10.11: Satoshi Nakatani: Assist devices
  • 10.12: Thor Edvardsen: Cardiomyopathies, myocarditis, and the transplanted heart
  • 10.13: Damien Voilliot and Patrizio Lancellotti: Cardiac valves
  • 10.14: Mehdi Eskandari and Mark J. Monaghan: Echocardiography in transcatheter aortic valve implantation
  • 10.15: Mehdi Eskandari and Mark J. Monaghan: Transcatheter mitral valve repair: from edge-to-edge to annuloplasty
  • 10.16: Felix C. Tanner and Rolf Jenni: Prosthetic valve evaluation
  • 10.17: Petros Nihoyannopoulos and Julia Grapsa: Pulmonary hypertension and the right ventricle
  • 10.18: Arturo Evangelista and José Rodríguez-Palomares: Echocardiographic assessment: diseases of the aorta
  • 10.19: Bogdan Popescu, Maria-Magdalena Gurzun, and Carmen Ginghina: Atrial fibrillation
  • 10.20: Aleksandar N. Neskovic, Ivan Stankovic and Predrag Milicevic: Emergency echocardiography
  • Section 11. Cardiovascular magnetic resonance
  • Section editor: Dudley Pennell
  • 11.1: Alicia Maceira: Normal anatomy and function
  • 11.2: Sonia Nielles-Vallespin: Cardiovascular magnetic resonance physics, techniques, and contrast agents
  • 11.3: Jurg Schwitter: Coronary artery disease
  • 11.4: Matthias Friedrich and Fabian Siepen: Cardiomyopathies
  • 11.5: Sonya Babu-Narayan: Congenital heart disease
  • 11.6: Saul Myerson: Valvular heart disease
  • 11.7: Chun Yuan, Zach Miller, and Jianming Cai: Atherosclerosis imaging
  • 11.8: Jan Bogaert: Angiography
  • 11.9: Massimo Lombardi and Antonia Camporeale: Less common pathologies
  • Section 12. Cardiovascular computed tomography
  • Section editor: Stephan Achenbach
  • 12.1: Stephan Achenbach: Technology of cardiac computed tomography
  • 12.2: Todd C. Villines, Joshua Mitchell, and Michael K. Cheezum: Coronary calcium
  • 12.3: Koen Nieman: Coronary computed tomography angiography: detection of coronary artery stenosis
  • 12.4: Pál Maurovich-Horvat: Coronary computed tomography angiography: imaging of coronary atherosclerotic plaque
  • 12.5: Amita Singh, Noreen Nazir, Victor Mor-Avi, and Amit R. Patel: Computed tomography myocardial perfusion
  • 12.6: Victoria Delgado: Computed tomography for cardiac morphology, function, and valve disease
  • 12.7: Mohamed Marwan and Stephan Achenbach: Computed tomography for cardiac interventions
  • Section 13. Nuclear cardiology and positron emission tomography
  • Section editor: Philipp Kaufmann
  • 13.1: Alessia Gimelli and Riccardo Liga: Basic principles and technological state of the art: SPECT
  • 13.2: Frank Bengel: Basic principles and technological state of the art: PET
  • 13.3: Ronny R. Buechel and Aju P. Pazhenkottil: Basic principles and technological state of the art: hybrid imaging
  • 13.4: Juhani Knuuti, S. Richard Underwood, and Antti Saraste: Assessment of coronary artery disease: chronic stable angina
  • 13.5: Juhani Knuuti, S. Richard Underwood, and Antti Saraste: Assessment of coronary artery disease: imaging-guided management and therapy
  • 13.6: Danilo Neglia and Juhani Knuuti: Integration of stress nuclear imaging in the diagnostic and management algorithms of stable coronary artery disease
  • 13.7: Danilo Neglia and Juhani Knuuti: Assessment of coronary artery disease: nuclear myocardial perfusion imaging in specific patient populations
  • 13.8: Danilo Neglia and Oliver Gaemperli: Heart failure
  • 13.9: Fabien Hyafil, Dominique Le Guludec, and Oliver Gaemperli: Endocarditis and device infection
  • 13.10: Tobias A. Fuchs and Oliver Gaemperli: Infiltrative disease (amyloidosis/sarcoidosis)
  • 13.11: Philipp A. Kaufmann, Oliver Gaemperli, and Juhani Knuuti: Future potential
  • Section 14. Invasive imaging haemodynamics
  • Section editor: Carlo Di Mario
  • 14.1: Guy Heyndrickx and Carlo Di Mario: Invasive Imaging and Haemodynamics
  • 14.2: Carlo Di Mario, Serafina Valente, and Carlotta Sorini Dini: Coronary Angiography and Ventriculography
  • 14.3: Philip Dingli, Nicola Ryan, Nieves Gonzalo, and Javier Escaned: Intravascular ultrasound imaging
  • 14.4: Francesco Prati, Laura Gatto, Enrico Romagnoli, and Luca Di Vito: Optical coherence tomography
  • 14.5: Carlo Di Mario, Carlotta Sorini Dini, and Serafina Valente: Near InfraRed Spectroscopy
  • 14.6: Emanuele Barbato and Fabio Mangiacapra: Functional coronary assessment: FFR
  • 14.7: Justin Davies and Christopher Cook: Functional coronary assessment: iFRand other indices
  • Section 15. Selection of imaging techniques
  • Section editor: Jeroen Bax
  • 15.1: Jeroen J. Bax, Alexander R. van Rosendael, Laurens F. Tops, Nina Ajmone Marsan, and Victoria Delgado: Choice of imaging techniques
  • PART 3. Heart Diseases
  • Section 16. Genetics of CV diseases
  • Section editor: Heribert Schunkert
  • 16.1: Heribert Schunkert: Introduction
  • 16.2: Jodie Ingles, Charlotte Burns, and Laura Yeates: Genetic counselling
  • 16.3: Eric Sijbrands: Principles of cascade screening
  • 16.4: Eric Schulze-Bahr: Principles of molecular testing
  • 16.5: Eric Schulze-Bahr: Basic principles of genetic disease
  • 16.6: Andrea Mazzanti, Riccardo Maragna, and Sylvia Priori: The Genetics of Long QT Syndrome
  • 16.7: Erol Tülümen and Martin Borggrefe: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - short QT Syndrome
  • 16.8: Sonia Van Dooren, Dorien Daneels, Gudrun Pappaert, Maryse Bonduelle, and Pedro Brugada Terradellas: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - Brugada Syndrome
  • 16.9: Peter Schwartz and Lia Crotti: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - catecholaminergic polymorphic ventricular tachycardia
  • 16.10: Najim Lahrouchi, Elijah Behr, and Connie Bezzina: Post-mortem genetic testing in sudden death cases
  • 16.11: Philippe Charron and Carole Maupain: Genetics of cardiomyopathies - Hypertrophic cardiomyopathy
  • 16.12: Daniel Oehler, Benjamin Meder, and Hugo Katus: Genetics of cardiomyopathies - Dilated cardiomyopathy
  • 16.13: Eloisa Arbustini, Alessandro Di Toro, Lorenzo Giuliani, Nupoor Narula, Valentina Favalli: Left Ventricular Noncompaction
  • 16.14: Kalliopi Pilichou, Cristina Basso, Rudy Celeghin, and Gaetano Thiene: Genetics of cardiomyopathies - Arrhythmogenic Right Ventricular Cardiomyopathy
  • 16.15: Abdallah Fayssoil: Genetics of cardiomyopathies -Cardiac manifestations of mitochondrial diseases
  • 16.16: Frank Weidemann: Genetics of cardiomyopathies - Myocardial infiltration
  • 16.17: Dorien Schepers and Bart Loeys: Genetics of vascular diseases - Marfan syndrome and aortic diseases
  • 16.18: Daniela Barge-Schaapveld, Marco DeRuiter, Conny van Munsteren, and Monique Jongbloed: Structural diseases of the heart - Genetics of congenital heart diseases
  • 16.19: Sabine Klaassen: Structural diseases of the heart- Syndromes affecting the CV System
  • 16.20: Heribert Schunkert: Complex Cardiovascular Diseases - Atherosclerosis - genetic factors
  • 16.21: Daniel Swerdlow, Steve Humphries, and Michael Holmes: Complex Cardiovascular Diseases - Dyslipidaemias - genetic factors
  • 16.22: Patrick Ellinor and Steven Lubitz: Genetic Determinants of Atrial Fibrillation
  • 16.23: Georg Ehert: The genetics of arterial hypertension
  • Section 17. Congenital heart disease (GUCH)
  • Section editor: John Deanfield
  • 17.1: John Deanfield: Introduction
  • 17.2: John Deanfield and Robert Andersen: Nomenclature
  • 17.3: John Deanfield and Bernard Keavney: Epidemiology and incidence
  • 17.4: Bernard Keavney and Elisavet Fotiou: Genetics
  • 17.5: Marietta Charakida: Fetal circulation & perinatal programming
  • 17.6: John Deanfield: Clinical Presentations & Initial Investigations
  • 17.7: Jan Marek, Folkert Meijboom, and Luc Mertens: Echocardiography in Congenital Heart Disease
  • 17.8: Giovanni Biglino, Silvia Schievano, and Andrew Taylor: Cross-Sectional imaging/modelling
  • 17.9: Alessandro Giardini: Functional Testing
  • 17.10: Henry Chubb and Martin Lowe: Arrhythmias in Childhood and Patients with Congenital Heart Disease
  • 17.11: Shakeel Qureshi: Interventional catheterization
  • 17.12: Michiel Winter, Berto Bouma, Barbara Mulder: Long term Outcomes
  • 17.13: Marietta Charakida: Arterial Disease in the Young
  • 17.14: Jolien Roos-Hesselink and Lucia Baris: Contraception and pregnancy
  • 17.15: Shahin Moledina: Pulmonary Hypertension
  • 17.16: Marc Gewillig: Heart Failure
  • 17.17: Dilveer Panesar and Mike Burch: Support/Transplant
  • 17.18: Marc Gewillig: Atrial Septal Defect (ASD)
  • 17.19: Michelle Carr: Atrioventricular Septal Defect (AVSD)
  • 17.20: Orla Franklin: Ventricular Septal Defect (VSD)
  • 17.21: Robert Yates: Patent Ductus Arteriosus (PDA)
  • 17.22: Robert Yates: Pulmonary Valve (PV) Stenosis
  • 17.23: Robert Yates: Vascular Rings
  • 17.24: David Anderson: Aortic Stenosis (AS) and Left Ventricular Outflow Tract Obstruction (LVOTO)
  • 17.25: Marietta Charakida: Coarctation
  • 17.26: Robert Yates: Tetralogy of Fallot (ToF)
  • 17.27: Sachin Khambadkone: Ebstein's Anomaly
  • 17.28: Alessandro Giardini: Hypoplastic Left Heart Syndrome (HLHS)
  • 17.29: Marc Gewillig: Single Ventricle/Total Cavopulmonary Connection (TCPC) (Fontan Circulation)
  • 17.30: Marietta Charakida and John Deanfield: Total Anomalous Pulmonary Venous Connection (TAPVC)
  • 17.31: John Deanfield and Marietta Charakida: Transposition of the Great Arteries (TGA)
  • 17.32: Robert Yates and Marietta Charakida: Congenitally corrected transposition of the great arteries
  • Section 18. Prevention in cardiovascular disease and rehabilitation
  • Section editor: Massimo Piepoli
  • 18.1: Massimo Piepoli: Introduction
  • 18.2: Yvo M. Smulders, Marie-Therese Cooney, and Ian Graham: Cardiovascular risk estimation at the individual level
  • 18.3: Guy De Backer, Johan De Sutter, and Ian M. Graham: Risk factor management at the level of the individual using lifestyle changes
  • 18.4: Eva Prescott, Torben Jørgensen, Maja-Lisa Løchen, Jonathan Pearson-Stuttard, Simon Capewell, and Maja Lisa Løchen: Risk factor intervention at the population level
  • 18.5: Ugo Corrà: Cardiac rehabilitation and exercise training
  • 18.6: Ugo Corrà: Prevention in cardiovascular disease and rehabilitation
  • 18.7: Christi Deaton, Margaret Cupples, and Kornelia Kotseva: Settings and stakeholders
  • Section 19. Diabetes mellitus metabolics syndrome
  • Section editor: Lars Ryden
  • 19.1: Lars Ryden: Introduction
  • 19.2: Jaakko Tuomilehto and Lars Ryden: Dysglycaemia - Definition, classification and diagnosis
  • 19.3: Francesco Cosentino: Vascular complications to dysglycaemia
  • 19.4: Nikolaus Marx: Cardiovascular risk assessment in dysglycaemic patients
  • 19.5: Linda Mellbin and Lars Ryden: Preventing cardiovascular complications in patients with dysglycemia
  • 19.6: Baris Gencer and Marco Roffi: Special conditions - Acute coronary syndromes
  • 19.7: Miguel Sousa Uva: Special conditions - Revascularisation
  • 19.8: Karl Swedberg: Special conditions - Heart failure
  • 19.9: Heikki Huikuri and Lars Ryden: Diabetes and Arrhythmia
  • 19.10: Lucia Mazzolai, Marianne Brodmann, and Victor Aboyans: Diabetes and lower extremity arterial disease
  • 19.11: Henrik Per Groop and Drazenka Pongrac Barlovic: Kidney disease
  • 19.12: Asa Hornsten: Person centred care
  • Section 20. Heart and the brain
  • Section editor: Hans-Christoph Diener
  • 20.1: Hans-Christoph Diener: Acute ischaemic stroke: classification and diagnosis
  • 20.2: Christoph Kleinschnitz: Impact of stroke on heart function
  • 20.3: Stefan Hohnloser: Causes of cardioembolic stroke
  • 20.4: Hans-Christoph Diener: Embolic stroke of undetermined source
  • 20.5: Heinrich P. Mattle and Simon Jung: Treatment of acute stroke
  • 20.6: David R. Holmes Jr, Guy S. Reeder, and Heinrich Mattle: Closure of a patent foramen ovale for the prevention of stroke
  • 20.7: Hans-Christoph Diener: Secondary stroke prevention in patients with atrial fibrillation
  • 20.8: Martin O'Donnell and Cliona Small: Management of vascular risk factors and co-morbidities in secondary stroke prevention
  • 20.9: Heinrich Mattle, Marcel Arnold, and Urs Fischer: Intracranial haemorrhage in patients with atrial fibrillation on anticoagulants
  • 20.10: Hans-Christoph Diener and John Camm: Atrial Fibrillation and dementia
  • Section 21. Cardiovascular problems in chronic kidney disease
  • Section editor: Christoph Wanner
  • 21.1: Stephan Segerer and Harald Seeger: Epidemiology and chronic kidney disease as a cardiovascular risk factor
  • 21.2: Thomas F. Mueller and Valerie Luyckx: Causes of death in renal disease
  • 21.3: Christoph Wanner: Pathophysiology
  • 21.4: Victoria Delgado: Cardiovascular imaging in chronic kidney disease
  • 21.5: Stephan Segerer and Harald Seeger: Prevention and drug therapy in chronic kidney disease
  • 21.6: Petra Nijst and Wilfried Mullens: Device therapy in chronic kidney disease (implantable cardioverter defibrillator, cardiac resynchronization therapy)
  • 21.7: Thomas F. Mueller and Valerie Luyckx: Special considerations in patients undergoing renal replacement therapy and kidney transplant patients
  • Section 22. Erectile dysfunction
  • Section editor: Charalambos Vlachopoulos
  • 22.1: Piero Montorsi: Sex and the heart
  • 22.2: Michael Doumas and Chrysoula Boutari: Erectile dysfunction: definition and size of the problem
  • 22.3: Tiny Jaarsma: Asking
  • 22.4: Charalambos Vlachopoulos and Nikolaos Ioakeimidis: Erectile dysfunction as a marker and predictor of cardiovascular disease
  • 22.5: Geoffrey Hackett: Testosterone, erectile dysfunction, and the heart
  • 22.6: Kevan R. Wylie: Sexual function and dysfunction in women (and the effect for the couple)
  • 22.7: Michael Kirby: Lifestyle issues
  • 22.8: Mike Kirby and Jonny Coxon: Drugs
  • 22.9: Odunayo Kalejaiye, Amr Abdel Raheem, and David Ralph: Surgery
  • 22.10: Charalambos Vlachopoulos, Nikolaos Ioakeimidis, and Dimitris Tousoulis: Management of a patient with erectile dysfunction with or without known cardiovascular disease
  • Section 23. Lung Disease
  • Section editor: Martin Cowie
  • 23.1: Kieran Rothnie and Jennifer Quint: Epidemiological relationships between respiratory and cardiovascular diseases
  • 23.2: Antia Simonds: Long Term Oxygen Therapy/Ventilation and Cardiovascular outcomes in chronic lung and respiratory disease
  • 23.3: Jennifer Quint: Effect of COPD treatment on CV outcome
  • 23.4: Michael Polkey: Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) (and heart failure)
  • 23.5: William Man and Rachael Evans: Pulmonary rehabilitation in Chronic Lung Disease and Heart Failure
  • 23.6: Olaf Oldenburg: Sleep apnoea: definition, prevalence and role in cardiovascular diseases
  • 23.7: Melissa Lipford and Virend Somers: Sleep Related Breathing Disorders - Classification and diagnosis
  • 23.8: Holger Woehrle and Michael Arzt: Diabetes and Arrhythmia
  • 23.9: Bernardo Selim: Sleep apnoea - Treatment options and sleep/CV
  • 23.10: Mark Miller, Anoop Shah, Nicholas Mills, and Dave Newby: Diabetes and lower extremity arterial disease
  • 23.11: Samuel Verges and Patrick Levy: Kidney disease
  • Section 24. Gastrointestinal disease
  • Section editor: Gerhard Rogler
  • 24.1: Gerhard Rogler: Introduction
  • 24.2: Eduard F. Stange: Gut microbiome, metabolic syndrome, and atherosclerosis
  • 24.3: Slayman Obeid, Melroy Miranda, and Thomas F. Lüscher: Gut microbiota and coronary artery disease
  • 24.4: Giuseppe Rosano: The gut and cardiovascular diseases
  • 24.5: Gerd A. Kullak-Ublick and Regina Krattinger: Intestinal absorption and drug levels
  • 24.6: Felix Stickel, Matteo Montani, and Christian Datz: Chronic heart failure and liver function
  • 24.7: Conall Morgan and Luc Mertens: Protein-losing enteropathy associated with heart disease
  • Section 25. Rheumatoid arthritis and the heart
  • Section editor: Thomas Lüscher
  • 25.1: Thomas F. Lüscher: Introduction
  • 25.2: Roland Klingenberg and Ulf Müller-Ladner: Mechanisms of inflammation
  • 25.3: Luigi Marzio Biasucci and Giovanna Liuzzo: Inflammatory diseases: inflammation and cardiovascular disease
  • 25.4: Oliver Distler and Caroline Ospelt: Rheumatoid arthritis: basic mechanisms in joints
  • 25.5: Thomas F. Lüscher and Paul M. Ridker: Anti-inflammatory therapies for cardiovascular disease
  • 25.6: Oliver Distler and Adrian Ciurea: Treatment aims in rheumatoid arthritis
  • 25.7: Gerhard Rogler: Inflammatory bowel disease: basic mechanisms
  • 25.8: Christian M. Matter, Stephan Winnik, and Gerhard Rogler: Inflammatory bowel disease and the heart
  • 25.9: Alexander A. Navarini: Psoriasis
  • Section 26. Rheumatic heart disease
  • Section editor: Ferande Peters
  • 26.1: Ferande Peters: Introduction
  • 26.2: Liesl Zühlke: Epidemiology of acute rheumatic fever and rheumatic heart disease
  • 26.3: Liesl Zühlke: Pathogenesis: from acute rheumatic fever to rheumatic heart disease
  • 26.4: Antoinette Cilliers: Clinical features and diagnosis of acute rheumatic fever
  • 26.5: Ferande Peters, Ruchika Meel, and Mohammed R. Essop: Echocardiography in acute rheumatic fever and rheumatic heart disease
  • 26.6: Liesl Zühlke: Prevention and definitive therapy of acute rheumatic fever
  • 26.7: Ferande Peters, Mpiko Ntsekhe, and Mohammed Essop: Chronic rheumatic disease
  • 26.8: Mohammed Essop, Mpiko Ntsekhe, and Ferande Peters: Clinical scenarios in chronic rheumatic heart disease
  • 26.9: Mohammed Essop: Therapeutic options in chronic rheumatic heart disease
  • Section 27. Cardio-oncology
  • Section editor: John Groarke
  • 27.1: John Groarke: Introduction
  • 27.2: Ersilia M. DeFilippis and Anju Nohria: Radiation-induced heart disease: surveillance and management
  • 27.3: Cian P. McCarthy, Michael T. Osborne, and Tomas G. Neilan: Surveillance for cardiotoxicity in patients receiving potentially cardiotoxic chemotherapy
  • 27.4: Daniela Cardinale and Carlo Maria Cipolla: Anthracycline-related cardiotoxicity: epidemiology, surveillance, prophylaxis, management, and prognosis
  • 27.5: Torbjørn Omland: Trastuzumab-related cardiotoxicity: epidemiology, surveillance, management, prophylaxis, and prognosis
  • 27.6: Mark Sweeney and Alexander Lyon: Cardiovascular complications of novel kinase inhibitors
  • 27.7: Daniel J. Lenihan: Cardiovascular complications of novel multiple myeloma treatments
  • 27.8: Daniel Perry, Megan Caram, and Monika Leja: Cardiovascular risk in men with prostate cancer
  • 27.9: John Keaney: Cardiac arrhythmias and cancer therapies
  • Section 28. HIV
  • Section editor: Nombulelo P. Magula
  • 28.1: Nombulelo P. Magula and Akira Singh: Introduction
  • 28.2: Giuseppe Barbaro: Epidemiology of HIV-associated cardiovascular complications
  • 28.3: Ntobeko A. B. Ntusi: HIV-associated cardiomyopathy and myocarditis
  • 28.4: Rubeshan Perumal and Nombulelo P. Magula: Pericarditis and myopericarditis in HIV
  • 28.5: Darrin Ryan Naidoo and Sherlina Kasipersad: Vascular disease: coronary, stroke, and peripheral vascular disease
  • 28.6: Anastase Dzudie and Friedrich Thienemann: Pulmonary hypertension: definitions, classification, diagnosis, and management
  • 28.7: Nombulelo P. Magula, Rubeshan Perumal, and Ruffin Apalata: Antiretroviral treatment
  • Section 29. Acute coronary syndromes
  • Section editor: Stefan James
  • 29.1: Stefan James and Marco Roffi: Introduction
  • 29.2: Michael Joner and Philipp Nicol: The plaque
  • 29.3: Héctor Bueno: Epidemiology of acute coronary syndromes
  • 29.4: Lene Rørholm Pedersen and Eva Prescott: General risk factors of acute coronary syndromes
  • 29.5: Giovanna Liuzzo, Daniela Pedicino, and Filippo Crea: Pathophysiology of acute coronary syndromes
  • 29.6: Robert Storey and William Parker: Thrombotic response
  • 29.7: Pascal Vranckx: Development of myocardial infarction
  • 29.8: Christian Mueller: Diagnosis and risk stratification of acute coronary syndromes
  • 29.9: Marco Valgimigli and Marco Angelillis: Treatment of non-ST elevation acute coronary syndromes
  • 29.10: Borja Ibanez and Sigrun Halvorsen: Treatment of ST elevation acute coronary syndromes
  • Section 30. Takotsubo syndrome
  • Section editor: Christian Templin
  • 30.1: Christian Templin: Introduction
  • 30.2: Abhiram Prasad: Incidence and definition of takotsubo syndrome
  • 30.3: Leonarda Galiuto and Filippo Crea: Mechanisms of takotsubo syndrome
  • 30.4: John D. Horowitz, Thanh Ha Nguyen, Sven Y. Surikow, Gao Jing Ong, Cher-Rin Chong, Dana K. Dawson, and Michael P. Frenneaux: Signal transduction pathways initiated by catecholamines in takotsubo syndrome: focus on nitrosative stress and energetic impairment
  • 30.5: Jelena R. Ghadri: Triggers of takotsubo syndrome
  • 30.6: Ilan Wittstein: Clinical presentation of takotsubo syndrome
  • 30.7: Rodolfo Citro and Eduardo Bossone: Diagnostic testing in takotsubo syndrome
  • 30.8: Federico Migliore, Sebastiano Gili, and Domenico Corrado: ECG features and arrhythmias in takotsubo syndrome
  • 30.9: Ken Kato, Sebastiano Gili, Fabio Fabbian, and Roberto Manfredini: Co-morbidities in takotsubo syndrome
  • 30.10: John E. Madias: Management of takotsubo syndrome
  • 30.11: Scott W. Sharkey: Takotsubo syndrome complications, outcome, and prognosis
  • Section 31. Genetics of CV diseases
  • Section editor: William Wijns
  • 31.1: William Wijns: Introduction
  • 31.2: Michael Joner, Kristin Steigerwald, and Anna Bulin: Pathology of Stable Coronary Artery Disease
  • 31.3: Nils Johnson and K. Gould: Pathophysiology of coronary circulation
  • 31.4: Filippo Crea and Gaetano Lanza: Myocardial ischemia: definition and causes
  • 31.5: Christian Seiler: Importance of the Coronary Collateral Circulation
  • 31.6: Jeroen Bax: Coronary artery disease: from atherosclerosis to obstructive disease, inducible ischemia and the ischemic cascade
  • 31.7: Ulrich Fischer-Rasokat and Christian Hamm: Clinical symptoms of stable ischemic heart disease
  • 31.8: Juhani Knuuti and Antti Saraste: Non invasive functional evaluation
  • 31.9: Stephan Achenbach: Non invasive (CT) and invasive angiography
  • 31.10: Keith Oldroyd and Colin Berry: Invasive Functional Evaluation of Patients with Chronic Ischaemic Heart Disease
  • 31.11: Nicola Ryan, Nieves Gonzalo, and Javier Escaned: Intracoronary imaging
  • 31.12: Vasim Farooq, Patrick Serruys, and Ply Chichareon: Risk stratification and risk scores
  • 31.13: Nicolas Danchin, Etienne Puymirat, and Nadia Aissaoui: Medical management: lifestyle and behavioural changes
  • 31.14: Aviv Shaul and David Hasdai: Medical management: pharmacological therapy
  • 31.15: Jean Claude Tardif, Philippe L?Allier, and Fabien Picard: Myocardial revascularization: symptomatic and prognostic indications
  • 31.16: Ruben Osnabrugge and Pieter Kappetein: Cost Effectiveness
  • 31.17: Ran Kornowski and Eli Lev: Patient Reported Outcome Measures in Cardiovascular Disease
  • 31.18: Ruben Osnabrugge and Pieter Kappetein: IHD and Diabetes
  • 31.19: Daniele Giacoppo and Robert Byrne: Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting
  • 31.20: Alessia Azzano and Stefan Verheye: Refractory angina
  • 31.21: Ward Heggermont, Marc Vanderheyden, and Jozef Bartunek: Chronic ischemic cardiomyopathy
  • 31.22: Paolo Camici and Ornella Rimoldi: Microvascular angina
  • 31.23: Peter Ong and Udo Sechtem: Vasospastic angina
  • Section 32. Myocardial disease
  • Section editor: Perry Elliott
  • 32.1: Perry Elliott: Introduction
  • 32.2: Eloisa Arbustini, Valentina Favalli, Alessandro Di Toro, Alessandra Serio, and Jagat Narula: Classification of cardiomyopathies
  • 32.3: Claudio Rapezzi and Massimiliano Lorenzini: General approach to diagnosis of cardiomyopathies
  • 32.4: Mohammed Akhtar and Luis Lopes: Hypertrophic Cardiomyapathy - Genetics of HCM
  • 32.5: Albert Hagege: Hypertrophic Cardiomyapathy - HCM: Diagnosis and assessment of symptoms
  • 32.6: Iacopo Olivotto: Hypertrophic Cardiomyapathy - HCM: Medical management of heart failure symptoms and arrythmia
  • 32.7: Steve Omen: Hypertrophic Cardiomyapathy - HCM: Invasive management of left ventricular outflow tract obstruction
  • 32.8: Constantinos O'Mahony: Hypertrophic Cardiomyapathy - HCM: Prevention of sudden cardiac death
  • 32.9: Luis Lopes: Dilated Cardiomyopathy - DM: Genetics
  • 32.10: Gianfranco Sinagra, Marco Merlo, and Davide Stolfo: Dilated Cardiomyopathy - Clinical diagnosis and medical management
  • 32.11: Pier Lambiase and Rui Providencia: Dilated Cardiomyopathy - DCM: Management of arrythmia and prevention of sudden cardiac death
  • 32.12: Jens Mogensen: Restrictive cardiomyopathy
  • 32.13: Petros Syrris and Alexandros Protonotarios: Arrhythmogenic right ventricular cardiomypathy - ARVC: Genetics
  • 32.14: Cristina Basso, Barbara Bauce, and Gaetano Thiene: Arrhythmogenic right ventricular cardiomypathy - ARVC: Diagnosis
  • 32.15: Perry Elliott and Alexandros Protonotarios: Arrhythmogenic right ventricular cardiomypathy - ARVC: Management of symptoms and prevention of sudden cardiac death
  • 32.16: Pablo Garcia-Pavia and Fernando Dominguez: Left Ventricular non-compaction - LVNC: GENETICSand embryology
  • 32.17: Jens Mogensen and Torsten B. Rasmussen: Left ventricular non-compaction: diagnosis and clinical management
  • 32.18: Sabine Pankuweit: Myocarditis - Aetiology & histopathological diagnosis
  • 32.19: Alida Caforio, Renzo Marcolongo, and Sabino Iliceto: Myocarditis - Clinical presentation
  • 32.20: Ali Yilmaz and Anca Florian: Myocarditis - Imaging (Echo, CMR, nuclear)
  • 32.21: Peter Heinz Schultheiss and Felicitas Escher: Myocarditis - Treatment of myocarditis
  • 32.22: Denis Duboc: The Heart in Nueromuscular disease - Mitochondrial Disease
  • 32.23: Henning Bundgaard, Anna Axelsson, Alex Christensen, and Helle Petri: The Heart in Nueromuscular disease - Myotonic Dystrophy
  • 32.24: Karim Wahbi: The Heart in Neuromuscular disease - Duchenne and Limb Girdle Muscular Dystrophies
  • 32.25: Ales Linhart: The Heart Inherited Metabolic disorders - Lysomal and glycogen storage diseases
  • 32.26: Martha Grogan: Cardiac Amyloidosis
  • 32.27: Karen Sliwa and Denise Hilfiker-Kleiner: Peripartum Cardiomyopathy
  • 32.28: Juan Kaski and Gabrielle Norrish: Cardiomyopathies in Children and Adolescents
  • Section 33. Pericardial disease
  • Section editor: Yehuda Adler
  • 33.1: Michael Arad and Yehuda Adler: Overview of pericardial syndromes
  • 33.2: Massimo Imazio, Fiorenzo Gaita, and Yehuda Adler: Acute and recurrent pericarditis
  • 33.3: Antonio Brucato and Stefano Maggiolini: Pericardial effusion
  • 33.4: Arsen D. Ristic, Petar M. Seferovic, Bernhard Maisch, and Vladimir Kanjuh: Cardiac tamponade
  • 33.5: Antonis Pantazis, Karin Klingel, and Yishay Wasserstrum: Constrictive pericarditis
  • 33.6: Angelos G. Rigopoulos and Hubert Seggewiss: Pericardial masses and congenital abnormalities
  • 33.7: Dor Lotan and Yehuda Adler: Pericardial involvement in neoplastic disease
  • 33.8: Massimo Imazio and Fiorenzo Gaita: Multimodality imaging of pericardial diseases
  • 33.9: Bernhard Maisch, Arsen Ristic, Sabine Pankuweit, and Peter Seferovic: Interventional therapies for pericardial diseases
  • 33.10: George Krasopoulos: Surgical therapies for pericardial disease
  • 33.11: Yehuda Adler and Dor Lotan: What next?
  • Section 34. Tumours of the heart
  • Section editor: Gaetano Thiene
  • 34.1: Gaetano Thiene, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Cristina Basso: Masses and cardiac tumours: classification and diagnosis
  • 34.2: Cristina Basso, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Gaetano Thiene: Benign cardiac tumours
  • 34.3: Cristina Basso, Stefania Rizzo, Marialuisa Valente, Martina Perazzolo Marra, and Gaetano Thiene: Malignant tumours, pericardial tumours, and therapy
  • Section 35. Valvular heart disease
  • Section editor: Helmut Baumgartner
  • 35.1: Bernard Lung and Pieter Kappetein: Introduction and general comments
  • 35.2: Pilar Tornos Mas and Emmanuel Lansac: Aortic regurgitation
  • 35.3: Helmut Baumgartner and Thomas Walther: Aortic stenosis
  • 35.4: Raphael Rosenhek and Michele de Bonis: Mitral regurgitation
  • 35.5: Alec Vahanian: Mitral stenosis
  • 35.6: Patrizio Lancellotti and Michele de Bonis: Tricuspid regurgitation
  • 35.7: Michele DeBonis: Tricuspid stenosis
  • 35.8: Michele DeBonis: Combined and multiple valve diseases
  • 35.9: Bernard Iung and Johan Sjögren: Prosthetic valves
  • 35.10: Johan Holm and Bernard Iung: Management during non-cardiac surgery
  • 35.11: Johan Holm and Bernard Iung: Management during pregnancy
  • Section 36. Infective endocarditis
  • Section editor: Gilbert Habib
  • 36.1: Bernard Iung: Epidemiology and physiopathology
  • 36.2: Nuria Fernández-Hidalgo, María Nazarena Pizzi, and Pilar Tornos: Diagnosis
  • 36.3: Isidre Vilacosta and Carmen Olmos: Prognosis and complications
  • 36.4: José A. San Román and Javier López: Prosthetic valve endocarditis
  • 36.5: Maria Grazia Bongiorni and Andrea Di Cori: Cardiac device-related endocarditis
  • 36.6: José A. San Román and Javier López: Right-sided infective endocarditis
  • 36.7: Patrizio Lancellotti and Stella Marchetta: Non-bacterial thrombotic endocarditis
  • 36.8: Joey M. Kuijpers, Berto J. Bouma, and Barbara J. M. Mulder: Specific situations: congenital heart disease
  • 36.9: Gilbert Habib: Indications for surgery: guidelines
  • 36.10: Jean-François Obadia, Benoit Cosset, and Matteo Pozzi: Surgical techniques
  • 36.11: Bruno Hoen and Xavier Duval: Antibiotic prophylaxis and prevention of infective endocarditis
  • 36.12: Gilbert Habib: Conclusion and future directions
  • Section 37. Heart failure
  • Section editor: John McMurray
  • 37.1: Theresa McDonagh and Kaushik Guha: Epidemiology of Heart Failure
  • 37.2: Pietro Aldo Maggioni and Ovidiu Chioncel: Definition, epidemiology/burden of disease - HFrEF
  • 37.3: Lars Lund and Gianluigi Savarese: Definition, epidemiology/burden of disease - HFpEF
  • 37.4: Anna Stromberg and Tiny Jaarsma: Health related quality of life - Definition, epidemiology, burden of disease, interventions
  • 37.5: Pardeep Jhund: Heart Failure: Symptoms, signs and the ECG
  • 37.6: Chronic Heart Failure Diagnosis a Heart Failure with preserved Ejection Fraction
  • 37.7: Thomas Marwick: Chronic heart failure diagnosis - Imaging echocardiography
  • 37.8: Robert Manka and Sabrina Oebel: Chronic heart failure diagnosis - Imaging - cardiac MRI
  • 37.9: Christian Mueller: Chronic heart failure diagnosis - Biomarkers
  • 37.10: Perry Elliott: Chronic heart failure diagnosis - Genetics
  • 37.11: Vasiliki Bistola, John Parissis, and Gerasimos Filippatos: Estimating prognosis - Prognostic scores
  • 37.12: Arthur Richards: Estimating prognosis - Biomarkers
  • 37.13: Dipak Kotecha and Mitja Lainscak: Comorbidity (HFrEF and HFpEF) - Atrial fibrillation
  • 37.14: Mark Petrie and Kieran Doherty: Heart failure and diabetes mellitus
  • 37.15: Francesco Paneni and Massimo Volpe: Hypertension and Heart Failure
  • 37.16: Kevin Damman: Comorbidity (HFrEF and HFpEF) - Renal dysfunction
  • 37.17: Piotr Ponikowski: Comorbidity (HFrEF and HFpEF) - Anaemia/iron deficiency
  • 37.18: Stefan Anker and Stephan von Haeling: Comorbidities: Obesity, cachexia, sarcopenia, and the impact of nutrition
  • 37.19: Comorbidity (HFrEF and HFpEF) a Lung disease
  • 37.20: Martin Cowie: Comorbidity (HFrEF and HFpEF) - Sleep disordered breathing
  • 37.21: Thomas Suter: Comorbidity (HFrEF and HFpEF) - Cancer
  • 37.22: Luc Pierard: Heart failure due to valvular heart disease
  • 37.23: Rhondalyn Forde-McLean and Mariell Jessup: Diuretic Use in Heart Failure with Reduced Ejection Fraction
  • 37.24: Marc Pfeffer: ACEI and or ARBs in Heart Failure and reduced Ejection Fraction
  • 37.25: John McMurray: Angiotensin receptor-neprilysin inhibitors
  • 37.26: Simon Beggs and Roy Gardner: Beta blockers in heart failure with reduced ejection fraction
  • 37.27: Michel Komajda: HFrEF pharmacological treatment - Ivabradine
  • 37.28: John Cleland and Yura Mareev: Heart Failure with a Reduced Left Ventricular Ejection Fraction (HFrEF) Pharmacological Treatment; Digitalis Glycosides
  • 37.29: Faraz Ahmad and Clyde Yancy: HFrEF pharmacological treatment - Hydralazine and isosorbide dinitrate
  • 37.30: Valentina Kutyifa: HFrEF other treatment - CRT/ICD
  • 37.31: Eric Velazquez and Mark Petrie: HFrEF other treatment - Revascularization
  • 37.32: Randall Starling and Emer Joyce: HFrEF other treatment - VADs
  • 37.33: Peter MacDonald and Kumud Dhital: Advanced Heart Failure other treatment - Transplantation
  • 37.34: Anna Stromberg and Tiny Jaarsma: HFrEF treatment - nurse led heart failure management programmes
  • 37.35: Maja Cikes and Scott Solomon: HFpEF treatment - Pharmacological therapy
  • 37.36: Dirk van Veldhuisen: Patient monitoring
  • 37.37: Alan Cohen-Solal: Exercise Rehabilitation in Heart Failure with reduced and preserved Ejection Fraction
  • 37.38: James Beattie: Palliative care in heart failure
  • 37.39: Adriaan Voors and Piotr Ponikowski: Acute heart failure - Diagnosis
  • 37.40: Javier Martin-Sanchez, Oscar Miro, and Hector Bueno: Acute heart failure - Immediate management/stabilization
  • 37.41: Dimitrios Farmakis, John Parissis, and Gerasimos Filippatos: Acute heart failure - Treatment
  • Section 38. Bradycardia
  • Section editor: Giuseppe Boriani
  • 38.1: Giuseppe Boriani: Introduction
  • 38.2: Fredrik Gadler and Cinzia Valzania: Aetiology and epidemiology of bradyarrhythmias
  • 38.3: Bulent Gorenek and Gulmira Kudaiberdieva: Classification of bradyarrhythmias
  • 38.4: Georges H. Mairesse: Methods and tools for the diagnosis of intermittent and persistent bradycardia
  • 38.5: Antonio Zaza: Anatomy and physiology of the sinus node
  • 38.6: Bruce Wilkoff and Corey Coleman: The sinus node: normal and abnormal chronotropic response and drug effects
  • 38.7: Jonathan M. Kalman and Gwilym M. Morris: Sinus node disease: pathophysiology and natural history
  • 38.8: Tatjana Potpara: Sinus node disease: ECG patterns and diagnosis
  • 38.9: Dominic A. M. J. Theuns: Sinus node disease: the role of electrophysiological testing
  • 38.10: Atrial tachyarrhythmias in bradycardiaatachycardia syndrome: characterization and evolution
  • 38.11: M. J. Pekka Raatikainen: Anatomy and physiology of the atrioventricular node
  • 38.12: S. Serge Barold: Atrioventricular conduction abnormalities and atrioventricular blocks: ECG patterns and diagnosis
  • 38.13: Demosthenes G. Katritsis and Mark E. Josephson: Atrioventricular conduction abnormalities and atrioventricular blocks: role of electrophysiology testing
  • 38.14: Drago Fabrizio and Battipaglia Irma: Congenital atrioventricular blocks: clinical presentation, clinical evaluation, and management
  • 38.15: Richard Sutton: Carotid sinus syndrome: clinical presentation, diagnosis, and management
  • 38.16: Hein Heidbuchel: Bradycardia in athletes: clinical evaluation and management
  • 38.17: Renato Pietro Ricci: Cardiac pacing: basic concepts
  • 38.18: Alexander Bauer: Temporary pacing
  • 38.19: Béla Merkely: Permanent cardiac pacing in bradyarrhythmias: device coding
  • 38.20: Jens Cosedis Nielsen and Jens Kristensen: Pacing for bradycardia: device features and algorithms and clinical impact
  • 38.21: Carsten Israel: Electrocardiographic patterns of cardiac pacemakers: normal and abnormal findings
  • 38.22: Anne M. Gillis: Follow-up of pacemaker patients with bradyarrhythmias: scope of follow-up and organizational issues
  • 38.23: Johannes Sperzel: Pacemakers in children and adolescents
  • 38.24: Jean Claude Deharo: Lead management
  • 38.25: Jan Steffel: Electromagnetic interference in pacemaker patients
  • 38.26: Giuseppe Boriani and Igor Diemberger: Pacemaker syndrome
  • Section 39. Syncope
  • Section editor: Michele Brignole
  • 39.1: J. Gert van Dijk and Roland D. Thijs: Definition, epidemiology, classification, and pathophysiology
  • 39.2: Frederik J. de Lange and J. Gert van Dijk: Diagnostic evaluation
  • 39.3: Jean-Claude Deharo: Reflex syncope
  • 39.4: Richard Sutton: Cardiac syncope
  • 39.5: Artur Fedorowski: Orthostatic intolerance: orthostatic hypotension and postural orthostatic tachycardia syndrome
  • 39.6: Vincent Probst and Jean-Baptiste Gourraud: Unexplained syncope in patients with high risk of sudden cardiac death
  • 39.7: Michele Brignole: Recommendations of the European Society of Cardiology Guidelines for the diagnosis and management of syncope (version 2018)
  • Section 40. Supraventricular tachycardias
  • Section editor: Carina Blomstorm-Lundqvist
  • 40.1: Carina Blomström-Lundqvist: Introduction
  • 40.2: Gregory Y. H. Lip: Epidemiology of supraventricular tachycardias
  • 40.3: Tatjana Potpara: Atrial premature beats
  • 40.4: Tatjana Potpara: Definitions, clinical presentation, symptoms, quality of life, and patient preferences
  • 40.5: Haran Burri: Differential diagnosis of supraventricular tachycardias
  • 40.6: Isabel Deisenhofer: Acute management of supraventricular tachycardias with and without established diagnosis (termination and/or rate regulation of tachycardia)
  • 40.7: Isabel Deisenhofer: Management of rapid heartbeats/tachycardias with rhythm or rate control in the absence of ECG-verified diagnosis
  • 40.8: Isabel Deisenhofer: Management of specific supraventricular tachycardias
  • 40.9: Brian Olshansky: Sinus node-related tachycardias: physiological sinus tachycardia, inappropriate sinus tachycardia, sinus node reentrant tachycardia, and postural orthostatic tachycardia syndrome
  • 40.10: Pierre Jaïs and Nicolas Derval: Atrial tachycardias: focal and multifocal atrial tachycardias
  • 40.11: Jose L. Merino: Atrial tachycardias: macroreentrant atrial tachycardias, CTI-dependent atrial flutter (clockwise, anticlockwise), and non-CTI-dependent macroreentrant atrial tachycardia
  • 40.12: Demosthenes G. Katritsis: Atrioventricular nodal reentrant tachycardia
  • 40.13: Jonathan Chrispin and Hugh Calkins: Accessory pathways-related tachycardias: Wolff-Parkinson-White syndrome and atrioventricular reentrant tachycardias
  • 40.14: Carlo Pappone and Vincenzo Santinelli: Concealed accessory pathways and related tachycardias
  • 40.15: Hildegard Tanner: Permanent junctional reciprocating tachycardia
  • 40.16: Carlo Pappone and Vincenzo Santinelli: Pre-excitation related to Mahaim physiology
  • 40.17: Jonathan Chrispin and Hugh Calkins: Asymptomatic pre-excitation
  • 40.18: Demosthenes G. Katritsis: Non-reentrant junctional tachycardias
  • 40.19: Giuseppe Boriani: Health economy
  • Section 41. Atrial fibrillation
  • Section editor: John Camm
  • 41.1: A. John Camm: Introduction
  • 41.2: Emelia Benjamin and Darae Ko: Epidemiology
  • 41.3: Ulrich Schotten: Mechanisms of atrial fibrillation: electrophysiological basis
  • 41.4: David O. Arnar and Hilma Holm: Mechanisms of atrial fibrillation: genetics
  • 41.5: David R. Van Wagoner: Mechanisms of atrial remodelling
  • 41.6: Larissa Fabritz, Ulrich Schotten, and Paulus Kirchhof: Types of atrial fibrillation
  • 41.7: Ben Freedman and Nicole Lowres: Silent atrial fibrillation
  • 41.8: Justin G. L. M. Luermans, Jordi Heijman, Isabelle C. Van Gelder, and Harry J. G. M. Crijns: Atrial fibrillation progression and prevention
  • 41.9: Hein Heidbuchel: Clinical investigation of patients presenting with atrial fibrillation
  • 41.10: Christian Sticherling and Michael Kuehne: Management of acute presentation with atrial fibrillation rate control
  • 41.11: Riccardo Cappato: Restoration of sinus rhythm: direct current cardioversion
  • 41.12: Irina Savelieva: Pharmacological cardioversion for atrial fibrillation
  • 41.13: Isabelle C. Van Gelder, Michiel Rienstra, Laurent Pison, and Harry J. G. M. Crijns: Rate control: medical therapy
  • 41.14: Maurizio Gasparini and Paola Galimberti: Rate control: ablation and device therapy (ablate and pace)
  • 41.15: Juan Tamargo: Rhythm control: antiarrhythmic drugs
  • 41.16: Gerhard Hindricks, Nikolaos Dagres, Philipp Sommer, and Andreas Bollmann: Development of atrial fibrillation catheter ablation and ablation strategies
  • 41.17: Chawannuch Ruaengsri, Matthew R. Schill, Richard B. Schuessler, and Ralph J. Damiano, Jr: Rhythm control: surgical ablation
  • 41.18: Albert L. Waldo: Rate versus rhythm control therapy for atrial fibrillation: a perspective
  • 41.19: Jeroen Hendriks: Follow-up of patients with atrial fibrillation
  • 41.20: Gregory Y. H. Lip: Stroke risk factors and risk stratification in atrial fibrillation
  • 41.21: Michael D. Ezekowitz and Amanulla N. Khaji: Stroke prevention in atrial fibrillation
  • 41.22: Margaret C. Fang: Bleeding risk in anticoagulated patients with atrial fibrillation
  • 41.23: Thorsten Lewalter, Clemens Jilek, and Peter Sick: Thromboprophylaxis in atrial fibrillation: device therapy and surgical techniques
  • 41.24: Eric M. Riles and Melvin Scheinman: Classification and mechanisms of atrial flutter
  • 41.25: Bhupesh Pathik and Jonathan M. Kalman: Atrial flutter: clinical presentation
  • 41.26: Tilman Maurer, Christine Lemes, and Karl-Heinz Kuck: Atrial flutter: management
  • 41.27: Johannes Brachmann: Atrial fibrillation and heart failure
  • 41.28: Eduard Guasch and Lluís Mont: Atrial fibrillation and athletes
  • 41.29: David Hirsh and Nanette Wenger: Atrial fibrillation in the elderly
  • 41.30: Rohan S. Wijesurendra and Barbara Casadei: Atrial fibrillation after cardiopulmonary surgery
  • 41.31: Hung-Fat Tse and Jo-Jo Hai: Atrial fibrillation and hypertension
  • 41.32: Bernadette Biondi: Atrial fibrillation and hyperthyroidism
  • 41.33: Rajiv Mahajan, Dennis H. Lau, and Prashanthan Sanders: Atrial fibrillation and obesity
  • 41.34: Jared D. Miller and Hugh G. Calkins: Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease
  • 41.35: Ken Okumura and Hirofumi Tomita: Atrial fibrillation and chronic kidney disease
  • 41.36: Jamie Conti, Mark Panna, and Michael Kaufmann: Atrial fibrillation in pregnancy
  • 41.37: Sunil Kapur and Saurabh Kumar: Atrial fibrillation associated with adult congenital heart disease
  • 41.38: Jeroen Hendriks: Integrated care management in atrial fibrillation
  • 41.39: Deirdre A. Lane: Patient education
  • Section 42. Ventricular tachycardia
  • Section editor: Brian Olshansky
  • 42.1: Nishant Verma and Bradley P. Knight: Classification of ventricular tachycardias
  • 42.2: Sei Iwai and Jason Jacobson: Evaluation and acute management of wide QRScomplex tachycardia
  • 42.3: Alfred E. Buxton: Classification and treatment of non-sustained ventricular tachycardia
  • 42.4: Fernando M. Contreras-Valdes and Peter J. Zimetbaum: Sustained monomorphic ventricular tachycardia associated with structural heart disease: classification, assessment, and initial treatment
  • 42.5: Akihiko Nogami: Bundle branch reentry tachycardia
  • 42.6: Len Ganz: Electrical storm
  • 42.7: Tilman Maurer,William G. Stevenson, and Karl-Heinz Kuck: Sustained monomorphic ventricular tachycardia: the role of catheter ablation
  • 42.8: Victor Bazan, Enrique Rodriguez-Font, and Francis E. Marchlinski: Sustained and non-sustained ventricular tachycardia and no associated heart disease (idiopathic ventricular tachycardia)
  • 42.9: L. Brent Mitchell: Polymorphic ventricular tachycardias including torsade de pointes
  • Section 43. Sudden Cardiac Death
  • Section editor: Gerhard Hindricks
  • 43.1: Harry Rakowski and Arnon Adler: Epidemiology, underlying substrates
  • 43.2: Pedro Brugada Terradellas and Juan Sieira: Arrhythmic mechanisms (bradycardia and tachycardia)
  • 43.3: Efstathios Iliodromitis and Dimitrios Farmaksis: Risk stratification for sudden cardiac death - in the general population
  • 43.4: Nikolaos Dagres and Gerhard Hindricks: Risk stratification for sudden cardiac death - in ischemic cardiomyopathy
  • 43.5: Dietmar Baensch: Risk stratification for sudden cardiac death - in dilated cardiomyopathy
  • 43.6: Wilhelm Haverkamp and Philipp Attanasi: Risk stratification for sudden cardiac death - in hypertrophic cardiomyopathy
  • 43.7: Firat Duru and Corinna Brunckhorst: Risk stratification for sudden cardiac death - in right ventricular cardiomyopathy
  • 43.8: Peter J. Schwartz and Lia Crotti: Risk stratification for sudden cardiac death - in primary electrical disorders
  • 43.9: Juan Fernandez-Armenta, Antonio Berruezo, Juan Acosta, and Diego Penela: New techniques for risk assessment
  • 43.10: Efstathios Iliodromitis and Dimitrios Farmaksis: Primary prevention of sudden cardiac death - in the general population
  • 43.11: Luigi Di Biase, Jorge Romero, Andrea Natale, Ricardo Avendano, and Mario Garcia: Primary prevention of sudden cardiac death - in ischemic cardiomyopathy
  • 43.12: Jens Cosedis Nielsen and Jens Kristensen: Secondary prevention of sudden cardiac death (in ischemic cardiomyopathy
  • 43.13: Riccardo Cappato: Primary prevention of sudden death - in Idiopathic dilated cardiomyopathy
  • 43.14: Riccardo Cappato: Secondary prevention of sudden cardiac death - in dilatedcardiomyopathy
  • 43.15: Barry Maron: Primary prevention of sudden cardiac death - in hypertrophiccardiomyopathy
  • 43.16: Wilhelm Haverkamp and Philipp Attanasio: Secondary prevention of sudden cardiac death - in hypertrophiccardiomyopathy
  • 43.17: Katja Zeppenfeld and Sebastiaan Piers: Primary prevention of sudden cardiac death - in right ventricular cardiomyopathy
  • 43.18: Katja Zeppenfeld and Sebastiaan Piers: Secondary prevention of sudden cardiac death - in right ventricular cardiomyopathy
  • 43.19: Josep Brugada and Elena Arbelo: Primary prevention of sudden cardiac death - in primary electrical disorders
  • 43.20: Josep Brugada and Elena Arbelo: Secondary prevention of sudden cardiac death - in primary electrical disorders
  • 43.21: Arash Arya: Secondary prevention of sudden cardiac death - after catheter ablation of ventricular tachycardia
  • 43.22: Gerhard Hindricks, Michael Kühl, and Nikolaos Dagres: The implantable cardioverter defibrillator. Conclusions on sudden cardiac death and future perspective
  • PART 4. Vascular disease
  • Section 44. Systemic hypertension
  • Section editor: Bryan Williams
  • 44.1: Stefano Taddei, Rosa Bruno, Masi Stefano, and Anna Solini: Epidemiology and Pathophysiology of Hypertension
  • 44.2: Gianfranco Parati: Classification of blood pressure and blood pressure measurement
  • 44.3: Giovanni De Simone: Target organ damage and CVD risk and clinical evaluation of the hypertensive patient
  • 44.4: Isabella Sudano: Secondary causes of hypertension
  • 44.5: Bryan Williams: Blood pressure Thresholds for treatment and blood pressure treatment targets in hypertension
  • 44.6: Francesco P Cappuccio: Sodium and potassium intake, blood pressure and cardiovascular prevention
  • 44.7: Michel Burnier, Sverre Kjeldsen, Anthony Heagerty, and Bryan Williams: Drug treatment of hypertension
  • 44.8: Felix Mahfoud: Device based treatment for hypertension
  • 44.9: Enrico Agabiti Rosei, Maria Lorenza Muiesan, and Massimo Salvetti: Hypertension in Specific conditions / comorbidities
  • 44.10: Thomas Kahan: Hypertension in Special situations
  • Section 45. Pulmonary Hypertension
  • Section editor: Marc Humbert
  • 45.1: Marc Humbert: Introduction
  • 45.2: Stephan Rosenkranz: Definition
  • 45.3: Rogerio Souza, Jose Leonidas Alves, and Susana Hoette: Epidemiology
  • 45.4: Christophe Guignabert, Ly Tu, Alice Huertas, and Marc Humbert: Pathophysiologic Mechanisms in Pulmonary Hypertension
  • 45.5: Florent Soubrier, Melanie Eyries, Barbara Girerd, David Montani, David Tregouet, and Marc Humbert: Genes of pulmonary hypertension as major diagnostic tools
  • 45.6: Joanne Groeneveldt, Anton Vonk Noordegraaf, and Frances de Man: Mechanisms of right ventricular failure
  • 45.7: Marion Delcroix and Catharina Belge: Clinical Presentation of Pulmonary Hypertension
  • 45.8: Marion Delcroix and Catharina Belge: Life-threatening complications of pulmonary hypertension
  • 45.9: Rogerio Souza, Francisca Oleas, and Caio Fernandes: Clinical classification
  • 45.10: Adam Torbicki: Echocardiographic findings in pulmonary hypertension
  • 45.11: John Coghlan: Screening for pulmonary hypertension
  • 45.12: Rogerio Souza, Daniela Calderaro, and Luis Felipe Prada: Diagnosis and clinical Investigation of patients presenting with pulmonary hypertension
  • 45.13: Stephan Rosenkranz: Management of pulmonary hypertension - Basic treatment
  • 45.14: Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini: Management of pulmonary hypertension: targeted therapies
  • 45.15: Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini: Management of pulmonary hypertension - Treatment algorithm
  • 45.16: Laurent Savale: Lung transplantation in pulmonary arterial hypertension
  • 45.17: Rogerio Souza, Carlos Jardim, and Luciana Morinaga: Idiopathic pulmonary arterial Hypertension
  • 45.18: Nicholas Morrell and Charaka Hadinnapola: Heritable pulmonary arterial Hypertension
  • 45.19: Irene Lang and Meinhard Kneussl: Pulmonary arterial Hypertension induced by drugs and toxins
  • 45.20: Chris Denton: Pulmonary arterial Hypertension associated with connective tissue disease
  • 45.21: Olivier Sitbon and Laurent Savale: Portopulmonary Hypertension
  • 45.22: Michael Gatzoulis, Margarita Brida, and Michel Gatzoulis: Pulmonary arterial Hypertension associated with congenital heart diseases
  • 45.23: Olivier Sitbon: Pulmonary Arterial Hypertension associated with HIV infection
  • 45.24: David Montani, Barbara Girerd, Edmund Lau, and Marc Humbert: Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatois
  • 45.25: Jean-Luc Vachiery: Pulmonary hypertension due to left heart diseases
  • 45.26: Ari Chaouat, Anne Guillaumot, Emmanuel Gomez, Olivier Huttin, Christine Suty-Selton, and Francois Chabot: Pulmonary hypertension due to chronic lung diseases
  • 45.27: Gerald Simonneau: Chronic thrombo-embolic pulmonary hypertension
  • 45.28: Andrew Peacock: Hypertension due to multiple and/or unclear mechanisms
  • 45.29: Simon Gibbs: Referral centres and patient education
  • 45.30: David Montani, Barbara Girerd, and Marc Humbert: Genetic counselling in pre-capillary pulmonary hypertension
  • 45.31: Marius Hoeper: Risk assessment and treatment goals in patients presenting with pulmonary arterial hypertension
  • 45.32: Marc Humbert: Conclusion
  • Section 46. Disease of the aorta
  • Section editor: Raimund Erbel
  • 46.1: Raimund Erbel: Introduction
  • 46.2: Raimund Erbel: The normal aorta
  • 46.3: Oliver Gaemperli and Udo Sechtem: Aortic aneurysm - Thoracic aortic aneurysm - Diagnostic approach
  • 46.4: Axel Haverich and Andreas Martens: Aortic aneurysm - Thoracic aortic aneurysm - Therapeutic options
  • 46.5: Roberto Bartolomeo, Alessandro Leone, Luca Di Marco, and Davide Pacini: Aortic aneurysm - Aortic arch aneurysms
  • 46.6: Regula von Allmen: Aortic aneurysm - Abdominal aortic aneurysm - Diagnostic Approach
  • 46.7: Regula von Allmen: Aortic aneurysm - Abdominal aortic aneurysm - Therapeutic options
  • 46.8: Yuvrajsinh Parmar and I. Kronzon: Aortic sclerosis - Clinical signs and diagnosis
  • 46.9: Raimund Erbel: Aortic sclerosis - Therapy
  • 46.10: Riccardo Gorla, Eduardo Bossone, and Raimund Erbel: Acute aortic syndrome - Diagnostic strategy and clinical features
  • 46.11: Toru Suzuki, Riccardo Gorla, and Eduardo Bossone: Acute aortic syndrome - Emerging role of biomarker
  • 46.12: Christoph Starck, Robert Hammerschmidt, and Volkmar Falk: Acute aortic syndrome - Aortic dissection - Ascending aortic dissection
  • 46.13: Rachel Clough, Xun Yuan, and Chirstoph Nienaber: Acute aortic syndrome - Aortic dissection - Descending aortic dissection
  • 46.14: Jae-Kwan Song: Acute aortic syndrome - Intramural Haematoma
  • 46.15: Arturo Evangelista and Jose Rodriguez-Palomares: Acute aortic syndrome - Penetrating aortic ulcer
  • 46.16: Johnny Steuer and Mario Lachat: Acute aortic syndrome - Traumatic aortic injury
  • 46.17: Ivan Nunez-Gil and Gisela Feltes: Acute aortic syndrome - latrogenic aortic trauma
  • 46.18: Dorien Schepers and Bart Loeys: Genetic diseases of the aorta - Chromosomal and inherited diseases
  • 46.19: Bernard Lung: Genetic diseases of the aorta - Aortic diseases associated with bicuspid aortic valves
  • 46.20: Folkert Meijboom and Gertjan Sieswerda: Genetic diseases of the aorta - Aortic diseases associated with bicuspid aortic valves
  • 46.21: Rosangela Cocchia, Riccardo Gorla, and Eduardo Bossone: Aortitis - infectious and non-infectious diseases
  • 46.22: Francesca Urgnani and Vicente Riambau: Aortic tumor
  • 46.23: Udo Sechtem and Oliver Gaemperli: Long-term follow-up in patients with aortic diseases
  • 46.24: Raimund Erbel: Role of aortic centers and aortic teams
  • Section 47. Trauma to the cardiovascular system
  • Section editor: Christoph Nienaber
  • 47.1: Ibrahim Akin and Christoph A. Nienaber: Trauma to the cardiovascular system
  • Section 48. Non-cardiac surgery
  • Section editor: Steen Kristensen
  • 48.1: Hans Erik Botker: Introduction and epidemiology
  • 48.2: Jose Gonzalez-Juanatey: Preoperative evaluation - Surgical risk for cardiac events Functional capacity Risk indexes
  • 48.3: Emmanuelle Duceppe and P.J. Devereaux: Preoperative evaluation - Biomarkers
  • 48.4: Juhani Knuuti and Antti Saraste: Preoperative evaluation - Non Invasive testing
  • 48.5: Hans Erik Botker: Preoperative evaluation - Angiography
  • 48.6: Emmanuelle Duceppe and P.J. Devereaux: Risk reduction strategies - Perioperative management of cardiovascular medication, Beta-blockers, Ivabradine, a2 receptor agonists, ACE-inhibitors, ATII-antagonists, Calcium antagonists
  • 48.7: Steen Kristensen, Michael Maeng, and Kurt Huber: Risk reduction strategies - Antiplatelet therapy; aspirin, P2Y12 inhibitors Anticoagulants: including NOACs,Withdrawal - continuation
  • 48.8: Marco Roffi and Fabio Rigamonti: Coronary revascularization before non-cardiac surgery
  • 48.9: Rodrigo Modolo and Ana Paula de Faria: Chronic Heart Failure / Hypertension
  • 48.10: Bernard Iung and Luc Pierard: Non-cardiac surgery Valvular heart disease
  • 48.11: Susanna Price and Evi Christodoulou: Specific diseases - Arrhythmias,VA, SupraVA, Bradyarrhythmias
  • 48.12: Susanna Price: Specific diseases - Renal
  • 48.13: Marco Roffi: Specific diseases - Neurological
  • 48.14: Susanna Price: Specific diseases - Pulmonary
  • 48.15: Luc Pierard: Peri-operative monitoring - TOE
  • 48.16: Susanna Price: Perioperative Monitoring - Right Heart catherization
  • 48.17: Susanna Price: Perioperative Monitoring - Glucose
  • 48.18: Stefan De Hert: Perioperative Monitoring - Anesthesiology
  • 48.19: Juhani Knuuti and Antti Saraste: Conclusions and recommendations
  • Section 49. Peripheral arterial diseases
  • Section editor: Victor Aboyans
  • 49.1: V Aboyans: Introduction
  • 49.2: Marie-Louise Bartelink: Epidemiology and risk factors
  • 49.3: Lucia Mazzolai: General aspects
  • 49.4: Jean Philippe Collet: Antithrombotic drugs in peripheral arterial diseases
  • 49.5: Ross Naylor: Extracranial carotid and vertebral artery disease
  • 49.6: Tina Conhert: Upper extremity artery disease
  • 49.7: Martin Björck: Mesenteric artery disease
  • 49.8: Charalambos Vlachopoulos: Renal artery disease
  • 49.9: Marianne Brodmann: Lower extremity artery disease
  • 49.10: Marco DeCarlo: Multisite artery disease
  • 49.11: Michal Tendera: Cardiac conditions in peripheral arterial diseases
  • 49.12: JB Ricco: Gaps in evidence
  • Section 50. Venous thromboembolism
  • Section editor: Stavros Konstantinides
  • 50.1: Stavros Konstantinides: Introduction
  • 50.2: Alexander Cohen, Marjolein Brekelmans, and Carlos Martinez: Epidemiology and socio-economic consequences of VTE
  • 50.3: Willem Lijfering and Suzanne Cannegieter: Predisposing factors for first and recurrent venous thrombosis
  • 50.4: Dieuwertje Ruigrok and Anton Vonk Noordegraaf: Pathophysiology
  • 50.5: Piotr Pruszczyk: Diagnosis - clinical prediction rules and laboratory tests
  • 50.6: Helia Robert-Ebadi, Gregoire Le Gal, and Marc Righini: Diagnosis of acute pulmonary embolism and evolving imaging modalities
  • 50.7: Cecilia Becattini and Giancarlo Agnelli: Prognostic assessment
  • 50.8: Thomas Vanassche and Peter Verhamme: Treatment - haemodynamic and respiratory support
  • 50.9: Cecilia Becattini and Giancarlo Agnelli: Treatment - anticoagulation
  • 50.10: Guy Meyer: Treatment - thrombolysis
  • 50.11: Ronald Winokur and Akhilesh Sista: Venous thromboembolism; Catheter Based Intervention and Inferior Vena Cava Filters
  • 50.12: Thijs van Mens and Saskia Middeldrop: Management of PEin pregnancy
  • 50.13: Cihan Ay and Florian Posch: Management of PEin patients with cancer
  • 50.14: Marc Rodger, Lisa Duffett, and Faizan Khan: Venous thrombosis: Risk of recurrence and optimal duration of anticoagulation
  • 50.15: Irene Lang,Walter Klepetko, and Hiromi Matsubara: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Section 51. Venous disease
  • Section editor: Sebastien Schellong
  • 51.1: Eberhard Rabe and Felizitas Pannier: Epidemiology and classification of venous disease
  • 51.2: Frederikus Klok, Charlotte Dronkers, and Menno Huisman: Venous imaging
  • 51.3: Jochen Grommes: Venous recanalisation
  • 51.4: Roshan Bootun, Tristan Lane, and Alun H. Davies: Varicose veins
  • 51.5: Robert Eberhardt and Joseph Raffetto: Chronic veous insufficiency/postthrombotic syndrome
  • PART 5. Specific Populations - gender and race
  • Section 52. Cardiovascular disease in women
  • Section editor: Noel Bairey Merz
  • 52.1: JoAnn E. Manson and Mariana Garcia: Background
  • 52.2: Eva Prescott: Sex and gender difference overview
  • 52.3: Karin Schenck-Gustafsson: Traditional cardiovascular disease risk factors
  • 52.4: Angela H. E. M. Maas: Non-traditional cardiovascular disease risk factors unique to or predominant in women
  • 52.5: Janet Wei: Cardiovascular disease prevention guidelines
  • 52.6: Martha Gulati: Ischaemic heart disease in women
  • 52.7: Vera Regitz-Zagrosek: Heart failure in women
  • 52.8: Sharon Mulvagh: Valvular heart disease
  • 52.9: Puja K. Mehta: Cardiac rehabilitation
  • 52.10: Mariana Garcia: Peripheral arterial disease in women
  • 52.11: C. Noel Bairey Merz: Future directions
  • Section 53. Pregnancy and heart disease
  • Section editor: Vera Regitz-Zagrosek
  • 53.1a: Janet Wei and C. Noel Bairey Merz: General considerations
  • 53.1b: Petronella Pieper: Pregnancy risk assessment
  • 53.2: Lisa-Antonia Droege and Wolfgang Henrich: Gynaecological, obstetric, and neonatological aspects
  • 53.3a: Jolien Roos-Hesselink and Annemien van den Bosch: Congenital heart disease and pulmonary hypertension
  • 53.3b: Bernard Iung: Aortic diseases
  • 53.4: Petronella G. Pieper and Bernard Iung: Valvular heart disease
  • 53.5: Angela H. E. M. Maas: Ischaemic heart disease in pregnancy
  • 53.6: Bozena Ostrowska, Barbara Kommata, Helena Malmborg, and Carina Blomström Lundqvist: Arrhythmias in pregnancy
  • 53.7: Vera Regitz-Zagrosek: Cardiomyopathies and heart failure
  • 53.8: Renata Cifkova: Hypertensive disorders
  • 53.9: Karen Sliwa and Mark R. Johnson: Venous thromboembolism in the peripartum period
  • 53.10: Stefan Verlohren: Drugs during pregnancy and breastfeeding
  • Section 54. Ethnicity
  • Section editor: Gregory H. Y. Lip
  • 54.1: Amitava Banerjee: Global perspectives of hypertension and cardiovascular disease
  • 54.2: Nizal Sarrafzadegan and Farzad Masoudkabir: Ethnicity and cardiovascular risk factors
  • 54.3: Adam Timmis: Ethnicity and coronary artery disease
  • 54.4: Bert-Jan van den Born and Charles Agyemang: Ethnicity and hypertension
  • 54.5: Tatjana Potpara: Ethnicity and cardiac arrhythmias
  • 54.6: Amitava Banerjee: Ethnicity and heart failure
  • 54.7: Larissa Fabritz: Ethnicity and inherited cardiac disease
  • 54.8: Bernard M. Y. Cheung and Esther W. Chan: Ethnic differences in responses to cardiovascular drugs
  • PART 6. Other aspects
  • Section 55. Sports and heart disease
  • Section editor: Antonio Pelliccia
  • 55.1: Michael Papadakis and Sanjay Sharma: Cardiovascular adaptation to exercise and sport (according to type of sport, gender, and ethnicity)
  • 55.2: Clinical assessment of the athleteas heart: normal and abnormal ECGs in athletes
  • 55.3: Antonio Pelliccia and Stefano Caselli: Imaging testing for differential diagnosis of the athlete's heart from structural cardiac diseases
  • 55.4: Eduard Guasch, Hein Heidbuchel, and Lluís Mont: Sudden cardiac death in athletes: implications for pre-participation evaluation and safety in sport arenas
  • 55.5: Massimo Piepoli: Exercise and sport in the management of cardiovascular diseases (ischaemic heart disease, heart failure, and hypertension)
  • Section 56. Elderly
  • Section editor: Franz Messerli and Tomasz Grodzicki
  • 56.1: Tomasz Grodzicki, Karolina Piotrowicz, and Jonna Sulicka: Multimorbidity and polypharmacy in the elderly with cardiovascular diseases
  • 56.2: Piotr Sobanski: Palliative and end-of-life care in elderly subjects with CVD
  • 56.3: Timo Strandberg and Tuomo Nieminen: Dementia and CVD
  • 56.4: Antonio Cherubini and Massimiliano Fedecostante: Frailty, Sarcopenia and Falls and CVD
  • 56.5: Nicola Veronese, Ludovico Carrino, and Stefania Maggi: Socio-economic issues and CVD (with emphasis on the caregivers)
  • 56.6: Andreas Schoenenberger: Comprehensive geriatric assessment in CVD
  • 56.7: Edgar Argulian: Degenerative cardiovascular disease in elderly
  • 56.8: Stefano Rimoldi: Lessons from ESCGuidelines
  • 56.9: Jerzy Gasowski, Chirag Bavishi, and Franz Messerli: Arterial Stiffness. From Isolated Systolic Hypertension to Syncope
  • 56.10: Joanna Kostka, Malgorzata Koziarska-Rosciszewska, and Tomasz Kostka: Elderly. Special situations (sport, physical activity, travel)
  • 56.11: Adrian Messerli and Khaled Ziada: Interventional Cardiology for the Elderly
  • Section 57. Precision medicine
  • Section editor: Paulus Kirchhof
  • 57.1: Paulus Kirchhof: Foundations of personalised medicine
  • 57.2: T. Kessler and Heribert Schunkert: Personalized management of coronary artery disease
  • 57.3: Karin Sipido and Tom Guzik: Disease mechanisms guiding therapy
  • 57.4: Larissa Fabritz, Eduard Guasch, Moritz Sinner, and Paulus Kirchhof: Personalised management of atrial fibrillation
  • 57.5: Stephan Baldus and Henrik ten Freyhaus: Individualized valve therapy
  • 57.6: Marina Cerrone, Morten Schak Nielsen, and Mario Delmar: Genetically-modified animals as tools to personalize the study of arrhythmia mechanisms and treatment
  • 57.7: Simon de Denus, Marie-Pierre Dubé, and Jean-Claude Tardif: Opportunities for personalized approaches in heart failure
  • 57.8: Andrea Mazzanti and Silvia Priori: Personalized Therapies for Cardiac Channelopathies
  • Section 58. Decision making and the heart team
  • Section editor: Patrick Serruys
  • 58.1: Vasim Farooq and Patrick W. Serruys: The Heart Team: introduction
  • 58.2: Vasim Farooq: Heart Teams in coronary artery disease
  • 58.3: Mohammad Abdelghani, Fahd Makhdom, and Nicolo Piazza: Decision-making and Heart Teams in valvular heart disease: the transcatheter aortic valve implantation team model
  • 58.4: Manuel Castella, Hans-Christoph Diener, Gerhard Hindricks, and Paulus Kirchhof: Heart Teams in atrial fibrillation
  • 58.5: Mohammad Abdelghani, Martina Nassif, Nico A. Blom, David R. Koolbergen, Barbara J. M. Mulder, and Robbert J. de Winter: Heart Teams in grown-up congenital heart disease
  • 58.6: Andras P. Durko, Stuart J. Head, and David P. Taggart: The Heart Team: conclusions and future perspectives
  • Section 59. Psychological factors and heart disease
  • Sectione editor: Susanne Pedersen
  • 59.1: Susanne Pedersen: Introduction
  • 59.2: Susanne Pedersen: Psychological factors and incident heart disease
  • 59.3: Frank Doyle: Psychological impact of heart disease
  • 59.4: Nina Kupper and Johan Denollet: Impact of psychological factors on outcomes
  • 59.5: Roland von Kaenel and Christian Albus: Mechanisms: psychological factors and outcomes
  • 59.6: Johan Denollet: The wider psychosocial context
  • 59.7: Interventions: what works for whoma
  • 59.8: Kim Smolderen: Clinical implications and future perspectives
  • 59.9: Susanne Pedersen: Conclusions
  • 59.10: Likely developments over the next 5a10 years
  • 59.11: Susanne Pedersen: Personal perspective
  • Section 60. Interpretation of clinical trials
  • Section editor: John Cleland
  • 60.1: John Cleland: Trial Design from a Clinical Perspective
  • 60.2: Tim Friede: Clinical Trial Design: Statistical Issues
  • 60.3: Muthiah Vaduganathan and Scott Solomon: Reporting Cardiovascular Clinical Trials
  • 60.4: Jan Tijssen: Principles and methods of intervention research
  • 60.5: Pardeep Jhund and John McMurray: Interpretation-2
  • 60.6: Colin Baigent and Natalie Staplin: Meta-analysis
  • Section 61. Environment
  • Section editor: Thomas Münzel
  • 61.1: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Summary
  • 61.2: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Introduction
  • 61.3: Thomas Münzel and Mette Sørensen: Pathophysiology of noise-induced cardiovascular diseases
  • 61.4: Robert D. Brook, David Newby, and Sanjay Rajagopalan: Pathophysiology of air pollution-mediated cardiovascular events
  • 61.5: Mette Sørensen and Thomas Münzel: Epidemiology of traffic noise and cardiometabolic disease
  • 61.6: Robert D. Brook, David Newby, and Sanjay Rajagopalan: Epidemiology of air pollution and cardiometabolic diseases
  • 61.7: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Strategies to mitigate cardiovascular effects of noise and air pollution
  • 61.8: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Future perspectives
  • 61.9: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Conclusions
  • 61.10: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Development and challenges over the next decade
  • Section 62. Occupational and regulatory aspects
  • Section editor: Demosthenes Katritsis
  • 62.1: Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe: Occupational risk factors for heart disease
  • 62.2: Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe: Regulations concerning individual risk and public safety
  • Section 63. Economics and cost-effectiveness
  • Section editor: Lorenzo Mantovani
  • 63.1: Lorenzo Mantovani: Introduction to health economics and cost-effectiveness of cardiovascular prevention
  • 63.2: Dyfrig Hughes: Health and economic impact of non-adherence to preventative cardiovascular medicines
  • 63.3: Giuseppe Boriani, Lucia D'Angiolella, and Fabiana Madotto: Economics of new therapies in electrophysiology
  • 63.4: Zaher Fanari, Sandra Weiss, and William S. Weintraub: Medical economics and interventional cardiology
  • 63.5: Lorenzo Mantovani and Lucia S. D'Angiolella: Economics of new therapies for heart failure, atrial fibrillation, and hypercholesterolaemia
  • PART 7. Appendices
  • A.1: Ian Graham, Marie Therese Cooney, Dirk De Bacquer, and Maryam Kavousi: Cardiovascular disease risk estimation
  • A.2: Polly Mitchell, Andrew Wragg, and Adam Timmis: Patient reported outcome measures
Προδιαγραφές προϊόντων
Εκδότες Oxford University Press
Εξώφυλλο Σκληρό
Σελίδες 2408
Έκδοση
Ημ. Έκδοσης December 2018
Γράψτε τη δική σου αξιολόγηση
  • Μόνο οι εγγεγραμμένοι χρήστες μπορούν να γράψουν σχόλια
  • Κακή
  • Άριστη
Προδιαγραφές προϊόντων
Εκδότες Oxford University Press
Εξώφυλλο Σκληρό
Σελίδες 2408
Έκδοση
Ημ. Έκδοσης December 2018
ISBN 9780198784906